
Bridget E. Bunner
Examiner (ID: 17180)
| Most Active Art Unit | 1647 |
| Art Unit(s) | 1647, 1644 |
| Total Applications | 1462 |
| Issued Applications | 724 |
| Pending Applications | 157 |
| Abandoned Applications | 602 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 6212351
[patent_doc_number] => 20110135651
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-06-09
[patent_title] => 'METHOD AND COMPOSITION FOR ENHANCING HEMATOPOIETIC STEM CELL MOBILIZATION'
[patent_app_type] => utility
[patent_app_number] => 13/057458
[patent_app_country] => US
[patent_app_date] => 2009-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 6308
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0135/20110135651.pdf
[firstpage_image] =>[orig_patent_app_number] => 13057458
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/057458 | METHOD AND COMPOSITION FOR ENHANCING HEMATOPOIETIC STEM CELL MOBILIZATION | Aug 17, 2009 | Abandoned |
Array
(
[id] => 6494066
[patent_doc_number] => 20100009918
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-01-14
[patent_title] => 'METHOD FOR THE ADMINISTRATION OF LIGANDS, AGONISTS OF LIGANDS OF THE TNF FAMILY WITH REDUCED TOXICITY'
[patent_app_type] => utility
[patent_app_number] => 12/542183
[patent_app_country] => US
[patent_app_date] => 2009-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5571
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0009/20100009918.pdf
[firstpage_image] =>[orig_patent_app_number] => 12542183
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/542183 | METHOD FOR THE ADMINISTRATION OF LIGANDS, AGONISTS OF LIGANDS OF THE TNF FAMILY WITH REDUCED TOXICITY | Aug 16, 2009 | Abandoned |
Array
(
[id] => 6477666
[patent_doc_number] => 20100041608
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-02-18
[patent_title] => 'METHOD FOR STIMULATING WOUND HEALING'
[patent_app_type] => utility
[patent_app_number] => 12/538714
[patent_app_country] => US
[patent_app_date] => 2009-08-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 6326
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0041/20100041608.pdf
[firstpage_image] =>[orig_patent_app_number] => 12538714
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/538714 | Method for stimulating wound healing | Aug 9, 2009 | Issued |
Array
(
[id] => 9523908
[patent_doc_number] => 08748170
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2014-06-10
[patent_title] => 'Polypeptides derived from cyclin B1 and uses thereof'
[patent_app_type] => utility
[patent_app_number] => 13/055907
[patent_app_country] => US
[patent_app_date] => 2009-07-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 2
[patent_no_of_words] => 3945
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13055907
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/055907 | Polypeptides derived from cyclin B1 and uses thereof | Jul 26, 2009 | Issued |
Array
(
[id] => 8398213
[patent_doc_number] => 08268592
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2012-09-18
[patent_title] => 'Anti-system ASC amino acid transporter 2 (ASCT2) antibody'
[patent_app_type] => utility
[patent_app_number] => 12/505133
[patent_app_country] => US
[patent_app_date] => 2009-07-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 19
[patent_no_of_words] => 50808
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 166
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12505133
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/505133 | Anti-system ASC amino acid transporter 2 (ASCT2) antibody | Jul 16, 2009 | Issued |
Array
(
[id] => 5958464
[patent_doc_number] => 20110182851
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-07-28
[patent_title] => 'OXIDIZED LDL SPECIFIC ANTIBODY-FUSION AND CONJUGATED PROTEINS'
[patent_app_type] => utility
[patent_app_number] => 13/003648
[patent_app_country] => US
[patent_app_date] => 2009-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 3551
[patent_no_of_claims] => 56
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0182/20110182851.pdf
[firstpage_image] =>[orig_patent_app_number] => 13003648
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/003648 | OXIDIZED LDL SPECIFIC ANTIBODY-FUSION AND CONJUGATED PROTEINS | Jul 12, 2009 | Abandoned |
Array
(
[id] => 7662283
[patent_doc_number] => 20110311552
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-12-22
[patent_title] => 'NOTCH1 RECEPTOR BINDING AGENTS AND METHODS OF USE THEREOF'
[patent_app_type] => utility
[patent_app_number] => 13/003013
[patent_app_country] => US
[patent_app_date] => 2009-07-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 33841
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0311/20110311552.pdf
[firstpage_image] =>[orig_patent_app_number] => 13003013
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/003013 | NOTCH1 receptor antibodies and methods of treatment | Jul 7, 2009 | Issued |
Array
(
[id] => 6314244
[patent_doc_number] => 20100111958
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-05-06
[patent_title] => 'Notch-Binding Agents and Antagonists and Methods of Use Thereof'
[patent_app_type] => utility
[patent_app_number] => 12/499627
[patent_app_country] => US
[patent_app_date] => 2009-07-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 44
[patent_figures_cnt] => 44
[patent_no_of_words] => 54826
[patent_no_of_claims] => 64
[patent_no_of_ind_claims] => 28
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0111/20100111958.pdf
[firstpage_image] =>[orig_patent_app_number] => 12499627
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/499627 | Antibodies to notch receptors | Jul 7, 2009 | Issued |
Array
(
[id] => 5972473
[patent_doc_number] => 20110152173
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-06-23
[patent_title] => 'TNF-a ANTAGONIST MULTI-TARGET BINDING PROTEINS'
[patent_app_type] => utility
[patent_app_number] => 13/001087
[patent_app_country] => US
[patent_app_date] => 2009-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 41179
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0152/20110152173.pdf
[firstpage_image] =>[orig_patent_app_number] => 13001087
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/001087 | TNF-a ANTAGONIST MULTI-TARGET BINDING PROTEINS | Jul 1, 2009 | Abandoned |
Array
(
[id] => 12283216
[patent_doc_number] => 09931386
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-04-03
[patent_title] => Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
[patent_app_type] => utility
[patent_app_number] => 12/483876
[patent_app_country] => US
[patent_app_date] => 2009-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 94
[patent_figures_cnt] => 101
[patent_no_of_words] => 22566
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12483876
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/483876 | Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity | Jun 11, 2009 | Issued |
Array
(
[id] => 7710113
[patent_doc_number] => 20120003181
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-01-05
[patent_title] => 'Novel Retinoid Inducible Factor and Uses Thereof'
[patent_app_type] => utility
[patent_app_number] => 12/997034
[patent_app_country] => US
[patent_app_date] => 2009-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 9958
[patent_no_of_claims] => 43
[patent_no_of_ind_claims] => 17
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12997034
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/997034 | Novel Retinoid Inducible Factor and Uses Thereof | Jun 8, 2009 | Abandoned |
Array
(
[id] => 6494254
[patent_doc_number] => 20100009934
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-01-14
[patent_title] => 'BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS'
[patent_app_type] => utility
[patent_app_number] => 12/480034
[patent_app_country] => US
[patent_app_date] => 2009-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 24520
[patent_no_of_claims] => 40
[patent_no_of_ind_claims] => 12
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0009/20100009934.pdf
[firstpage_image] =>[orig_patent_app_number] => 12480034
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/480034 | BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | Jun 7, 2009 | Abandoned |
Array
(
[id] => 6229863
[patent_doc_number] => 20100184091
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-07-22
[patent_title] => 'Method for determining MIF content'
[patent_app_type] => utility
[patent_app_number] => 12/477889
[patent_app_country] => US
[patent_app_date] => 2009-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 23
[patent_no_of_words] => 31349
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0184/20100184091.pdf
[firstpage_image] =>[orig_patent_app_number] => 12477889
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/477889 | Method for determining MIF content | Jun 2, 2009 | Abandoned |
Array
(
[id] => 6358893
[patent_doc_number] => 20100087358
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-04-08
[patent_title] => 'NOTCH mutations leading to increased receptor signaling'
[patent_app_type] => utility
[patent_app_number] => 12/453833
[patent_app_country] => US
[patent_app_date] => 2009-05-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 38
[patent_figures_cnt] => 38
[patent_no_of_words] => 11186
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0087/20100087358.pdf
[firstpage_image] =>[orig_patent_app_number] => 12453833
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/453833 | NOTCH mutations leading to increased receptor signaling | May 21, 2009 | Issued |
Array
(
[id] => 8293986
[patent_doc_number] => 08221765
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2012-07-17
[patent_title] => 'Multivalent fibronectin based scaffold domain proteins'
[patent_app_type] => utility
[patent_app_number] => 12/470989
[patent_app_country] => US
[patent_app_date] => 2009-05-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 43
[patent_figures_cnt] => 63
[patent_no_of_words] => 40316
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 234
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12470989
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/470989 | Multivalent fibronectin based scaffold domain proteins | May 21, 2009 | Issued |
Array
(
[id] => 5304118
[patent_doc_number] => 20090298770
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-12-03
[patent_title] => 'MAMMALIAN RELAXIN RECEPTORS'
[patent_app_type] => utility
[patent_app_number] => 12/426771
[patent_app_country] => US
[patent_app_date] => 2009-04-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 15641
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0298/20090298770.pdf
[firstpage_image] =>[orig_patent_app_number] => 12426771
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/426771 | MAMMALIAN RELAXIN RECEPTORS | Apr 19, 2009 | Abandoned |
Array
(
[id] => 5552287
[patent_doc_number] => 20090286273
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-11-19
[patent_title] => 'USE OF NEUREGULIN-BETA AS AN INDICATOR AND/OR TARGET'
[patent_app_type] => utility
[patent_app_number] => 12/424962
[patent_app_country] => US
[patent_app_date] => 2009-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 7259
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0286/20090286273.pdf
[firstpage_image] =>[orig_patent_app_number] => 12424962
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/424962 | Neuregulin-β isoform | Apr 15, 2009 | Issued |
Array
(
[id] => 6087865
[patent_doc_number] => 20110217294
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-09-08
[patent_title] => 'COMBINATION OF HGF INHIBITOR AND HEDGEHOG INHIBITOR TO TREAT CANCER'
[patent_app_type] => utility
[patent_app_number] => 12/935264
[patent_app_country] => US
[patent_app_date] => 2009-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 10703
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0217/20110217294.pdf
[firstpage_image] =>[orig_patent_app_number] => 12935264
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/935264 | COMBINATION OF HGF INHIBITOR AND HEDGEHOG INHIBITOR TO TREAT CANCER | Apr 8, 2009 | Abandoned |
Array
(
[id] => 5945113
[patent_doc_number] => 20110105733
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-05-05
[patent_title] => 'SINGLE VARIABLE DOMAINS AGAINST THE NOTCH PATHWAYS'
[patent_app_type] => utility
[patent_app_number] => 12/934766
[patent_app_country] => US
[patent_app_date] => 2009-04-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 90474
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0105/20110105733.pdf
[firstpage_image] =>[orig_patent_app_number] => 12934766
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/934766 | Single variable domains against notch pathway members | Apr 6, 2009 | Issued |
Array
(
[id] => 5928896
[patent_doc_number] => 20110038855
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-02-17
[patent_title] => 'TRAIL AND METHODS OF MODULATING T CELL ACTIVITY AND ADAPTIVE IMMUNE RESPONSES USING TRAIL'
[patent_app_type] => utility
[patent_app_number] => 12/417487
[patent_app_country] => US
[patent_app_date] => 2009-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 36612
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0038/20110038855.pdf
[firstpage_image] =>[orig_patent_app_number] => 12417487
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/417487 | TRAIL AND METHODS OF MODULATING T CELL ACTIVITY AND ADAPTIVE IMMUNE RESPONSES USING TRAIL | Apr 1, 2009 | Abandoned |